|
Note 8 - Collaborative and License Agreements (Details) (USD $)
|
0 Months Ended |
12 Months Ended |
0 Months Ended |
|
|
Jun. 30, 2014
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 11, 2014
|
May 29, 2013
|
Aug. 07, 2014
|
| Note 8 - Collaborative and License Agreements (Details) [Line Items] |
|
|
|
|
|
|
|
| Research and Development Expense |
|
$ 41,884,000 |
$ 33,221,000 |
$ 22,001,000 |
|
|
|
| Success Based Milestones, Maximum Payment |
5,000,000 |
|
|
|
|
|
|
| Collaborative Arrangement, Co-promotion [Member] | Upfront Payment [Member] | Array BioPharma Inc. [Member] |
|
|
|
|
|
|
|
| Note 8 - Collaborative and License Agreements (Details) [Line Items] |
|
|
|
|
|
|
|
| Research and Development Expense |
|
|
|
|
20,000,000 |
10,000,000 |
|
| Collaborative Arrangement, Co-promotion [Member] | Maximum [Member] | Array BioPharma Inc. [Member] |
|
|
|
|
|
|
|
| Note 8 - Collaborative and License Agreements (Details) [Line Items] |
|
|
|
|
|
|
|
| Contingent Payable |
|
|
|
|
280,000,000 |
|
|
| Collaborative Arrangement, Co-promotion [Member] | Array BioPharma Inc. [Member] |
|
|
|
|
|
|
|
| Note 8 - Collaborative and License Agreements (Details) [Line Items] |
|
|
|
|
|
|
|
| Contract Terms, Years from Effective date for Acquistion Restrictions |
|
|
|
|
3 years |
|
|
| Expiration Period Following First Commercial on A Country by Country Basis |
|
|
|
|
10 years |
|
|
| License Agreement Termination Notice Period |
|
|
|
|
180 days |
|
|
| Collaboration Agreement Termination Fees |
|
|
|
|
$ 0 |
|
|
| STC.UNM [Member] |
|
|
|
|
|
|
|
| Note 8 - Collaborative and License Agreements (Details) [Line Items] |
|
|
|
|
|
|
|
| Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners |
|
|
|
|
|
|
5.00% |